Achema middle east

Drug Research

Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition

Cryoport, Inc., a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, announced the acquisition of Tec4med Lifescience GmbH, a...

Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurmas portfolio companies

Samsung Biologics to provide de-risking, development, manufacturing services, and seamless transitions for biologics from early stages of development to large-scale commercialization The partnership will streamline gene to IND process to accelerate lead candidate selection and advance CMC along clinical development Multi-year...

Andelyn Biosciences and Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Purespring Therapeutics, a biotech innovator company, to accelerate the manufacture of their gene therapies for the treatment of chronic...

Roche – Biogen Settle US Patent Law Suit For Arthritis Drug

Based on a filing on October 23 in Massachusetts federal court, Roche, the Swiss pharmaceutical giant, has reached a settlement in a patent lawsuit against Biogen, which happens to be a U.S. biotech firm. The lawsuit was concerning Biogen's...

CDMO-Biotech Collab Diminish Business Risk In Drug Creation

Biotech companies go on to face numerous challenges, particularly while in the clinical phase of drug development, in today's fast-paced industry. The astronomically high costs, complicated manufacturing processes, as well as regulatory hurdles related to biologics can go on...

Vetter Further Invests €230M in New Production Building

Vetter, a global CDMO, is making additional investments as part of its long-lead goals for continued expansion and to support customer needs. The company is investing €230 million in its new production building, which is currently under construction at its...

Lonza to enhance commercial antibody-drug conjugate supply capacity

Lonza is planning to build a commercial-scale aseptic current good manufacturing practice (cGMP) filling line at its site in Stein, Switzerland. The new filling line will facilitate the aseptic filling of highly-potent antibody drug conjugates (ADCs) and lyophilisation under...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »